Dexcom Q4 revenue rises 13% to $1.260 billion; 2026 revenue guidance reiterated
Dexcom reported fourth-quarter 2025 revenue up 13% year over year to $1.260 billion and full-year 2025 revenue of $4.662 billion, up 16%. GAAP net income was $267.3 million, or $0.68 per diluted share, compared with $151.7 million, or $0.38 per diluted share, a year earlier. The company reiterated 2026 revenue guidance of $5.16 billion to $5.25 billion and set new Adjusted EBITDA Margin guidance of approximately 30% to 31%.
Key points
- Q4 2025 revenue was $1.260 billion, up 13% on a reported basis and 12% on an organic basis, from $1.114 billion in Q4 2024.
- GAAP operating income was $323.0 million, or 25.6% of revenue, versus $188.9 million in Q4 2024.
- 2026 guidance: revenue of $5.16 billion to $5.25 billion (reiterated) and Adjusted EBITDA Margin of approximately 30% to 31% (newly established).
- Cash, cash equivalents and marketable securities totaled $2.00 billion as of December 31, 2025; the revolving credit facility is undrawn.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.